SIRAs are centrally-acting antihypertensive drugs which are thought to target the imidazoline I1 receptor in the cardiovascular control centre in the brainstem.
Monoxidine is the first in this class of drug. Although better tolerated than the older centrally acting antihypertensives such as clonidine, there is no longterm outcome data.
SIRAs should be used when other treatments have been tried and have failed.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.